NY Judge Tosses $6.4B BMS Investor Action For Good
Celgene Corp. investors could not convince a New York federal judge that Bristol-Myers Squibb Co. was intentionally trying to flout securities law by delaying the U.S. Food and Drug Administration's approval...To view the full article, register now.
Already a subscriber? Click here to view full article